Title: nAChRs-ERK1/2-Egr-1 signaling participates in the developmental toxicity of nicotine by epigenetically down-regulating placental 11β-HSD2.
Journal: Toxicology and applied pharmacology 20180401
Title: IGF1/MAPK/ERK signaling pathway-mediated programming alterations of adrenal cortex cell proliferation by prenatal caffeine exposure in male offspring rats.
Journal: Toxicology and applied pharmacology 20180215
Title: Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity.
Journal: PloS one 20160101
Title: Cadmium promotes the proliferation of triple-negative breast cancer cells through EGFR-mediated cell cycle regulation.
Journal: Toxicology and applied pharmacology 20151115
Title: Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK pathway in human breast cancer MCF-7 cells.
Journal: Toxicology and applied pharmacology 20150815
Title: Antidepressant-like effect of sildenafil through oxytocin-dependent cyclic AMP response element-binding protein phosphorylation.
Journal: Neuroscience 20120103
Title: Critical role for ERK1/2 in bone marrow and fetal liver-derived primary megakaryocyte differentiation, motility, and proplatelet formation.
Journal: Experimental hematology 20091001
Title: Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Journal: The Journal of pharmacology and experimental therapeutics 20090601
Title: The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Journal: The Journal of surgical research 20081201
Title: A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment.
Journal: Biological psychiatry 20070301
Title: The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.
Journal: Neoplasia (New York, N.Y.) 20060101
Title: Aggravation of necrotic death of glucose-deprived cells by the MEK1 inhibitors U0126 and PD184161 through depletion of ATP.
Journal: Biochemical pharmacology 20040715
Title: Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Journal: Cancer research 20040701
